Advances in oral peptide drug nanoparticles for diabetes mellitus treatment.

Li, Yan et al.·Bioactive materials·2022·
RPEP-063082022RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Nanoparticles can significantly improve the oral bioavailability of peptide drugs.

Key Numbers

How They Did This

This is a review study that analyzes existing research on nanoparticles for oral peptide drug delivery.

Why This Research Matters

Improving the oral delivery of peptide drugs could lead to better patient compliance and treatment outcomes for diabetes. This research highlights innovative solutions to a common problem in drug delivery.

What This Study Doesn't Tell Us

As a review, it does not present new experimental data and relies on existing literature, which may vary in quality.

Trust & Context

Original Title:
Advances in oral peptide drug nanoparticles for diabetes mellitus treatment.
Published In:
Bioactive materials, 15, 392-408 (2022)
Database ID:
RPEP-06308

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-06308·https://rethinkpeptides.com/research/RPEP-06308

APA

Li, Yan; Zhang, Wen; Zhao, Ruichen; Zhang, Xin. (2022). Advances in oral peptide drug nanoparticles for diabetes mellitus treatment.. Bioactive materials, 15, 392-408. https://doi.org/10.1016/j.bioactmat.2022.02.025

MLA

Li, Yan, et al. "Advances in oral peptide drug nanoparticles for diabetes mellitus treatment.." Bioactive materials, 2022. https://doi.org/10.1016/j.bioactmat.2022.02.025

RethinkPeptides

RethinkPeptides Research Database. "Advances in oral peptide drug nanoparticles for diabetes mel..." RPEP-06308. Retrieved from https://rethinkpeptides.com/research/li-2022-advances-in-oral-peptide

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.